Rhythm Pharmaceuticals (RYTM) Reports In-Line Q1 EPS

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($2.35), in-line with the analyst estimate of ($2.35). Revenue for the quarter came in at $25.97 million versus the consensus estimate of $27.02 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Rhythm Pharmaceuticals (RYTM) PT Raised to $151 at Canaccord
• MP Materials seen largely insulated after China export-control move